Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues (Q34419660)

2 August 2017

1 reference

title

Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues (English)

1 reference

2 August 2017

0 references

Niederman MS

1

1 reference

2 August 2017

publication date

1 November 2001

1 reference

Medical Clinics of North America

2 August 2017

published in

1 reference

2 August 2017

volume

85

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

1493-1509

1 reference

Pneumococcal macrolide resistance--myth or reality?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

A prediction rule to identify low-risk patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Antimicrobial treatment of community acquired pneumonia in adults: A conference report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Evidence based medicine in critical care: will it take us over the cutting edge?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired Pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970392-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70392-8

1 reference

2 August 2017

1 reference